The Rising Prevalence of Severe Infectious Diseases Coupled with Government Initiatives, Has Enriched the Growth of The Global Conjugate Vaccine Market

Published: Jun 2022

The global conjugate vaccine market is anticipated to grow significantly at a CAGR of 10.2% during the forecast period (2021-2028). Globally the incidence of infectious diseases continue to have major health and economic costs. Infectious diseases such as Diphtheria, Influenza, Pneumococcal can catch people into poverty and can have devastating effect on the country’s economy. The rising prevalence of these diseases is the major factor contributing to the growth of the conjugated market. Also the awareness programmes run by various private or government organizations is giving momentum to the conjugate vaccine market. 

Browse the full report description of “Global Conjugate Vaccine Market Size, Share & Trends Analysis Report By Product Type (Multivalent Conjugate Vaccines, Monovalent Conjugate Vaccines) By Disease (Meningococcal, Diphtheria Tetanus Pertussis, Influenza, Pneumococcal, and Others) By Patient Type (Adults and Pediatrics) By Pathogen Type (Bacterial Conjugate Vaccine, Viral Conjugate Vaccine and Combination Vaccine) Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/conjugate-vaccine-market

For instance Ministry of Health & Family Welfare (MoHFW), Government of India, has implemented various routine immunization intensification strategies to reduce under-five morbidity mortality and disability due to vaccine preventable diseases by providing quality immunization services to all eligible populations. The main work of vaccines is to help cure the infectious diseases across the globe. Approximately 29.4 million children have been covered in 528 districts under this initiative. These initiatives are in turn contributing to the growth of the global conjuvate vaccine market. Moreover, invetsing on R&D activites for the development of new vaccines and launching new product in collaboration with other players operatig in conjugate vaccine market. Is significantly growing the global conjuvate vaccine market. 

Market Coverage

The market number available for – 2022-2028

Base year- 2021

Forecast period- 2022-2028

Segment Covered- by product type, by disease, by patient type , by pathogen type

Regions Covered- North America, Europe, Asia-Pacific, Rest of the World

Competitive Landscape- Astellas Pharma, Astrazeneca, Csl Behring and others.

Key questions addressed by the report

What is the market growth rate?

Which segment/region dominates the market in the base year?

Which segment/region will project the fastest growth in the market?

How has COVID-19 impacted the market?

o Recovery Timeline

o Deviation from the pre-COVID forecast

o Most affected region/segment

Who is the leader in the market?

How players are addressing challenges to sustain growth?

Where is the investment opportunity?

Global Conjugate Vaccine Market– Segmentation

By Product Type

  • Multivalent Conjugate Vaccines 
  • Monovalent Conjugate Vaccines 

By Disease

  • Meningococcal 
  • Diphtheria Tetanus Pertussis
  • Influenza
  • Pneumococcal
  • Others

By Patient Type

  • Adult 
  • Pediatrics 

By Pathogen Type

  • Bacterial Conjugate Vaccine 
  • Viral Conjugate Vaccine
  • Combination Vaccine

Global Conjugate vaccine Market by Region 

North America           

US

Canada

Europe

Germany

United Kingdom

France

Spain

Italy

Rest of Europe

Asia-Pacific    

China

Japan

India

Rest of Asia-Pacific

Rest of the World

Middle East & Africa 

Latin America 


To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/conjugate-vaccine-market